Buy Koselugo 25mg -28s Selumetinib

Koselugo 25mg capsules contain selumetinib, a medication used in certain cancer treatments. Store below 25°C and keep out of reach of children. Always follow healthcare provider instructions. This overview provides general information only.

Strength

25mg

Pack Size

28s

Storage

Below 25°C

Manufacturer / TM Owner

AstraZeneca Pharmaceuticals LP

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Uses / Indications

Selumetinib, the active ingredient in Koselugo 25mg capsules, is used to treat specific types of cancer in pediatric patients. It belongs to a class of drugs that help slow or stop cancer cell growth. Patients and caregivers often ask, what is selumetinib used for, particularly in neurofibromatosis type 1 (NF1) associated plexiform neurofibromas. Always consult a healthcare professional for personalized guidance.

Side Effects

Koselugo 25mg capsules may help reduce the size of tumors in eligible patients. Some users report improved comfort as treatment progresses. Effects vary by individual, and consistent use is important. Side effects can include fatigue, nausea, or skin reactions, but not everyone experiences them.

Precautions & Warnings

Keep Koselugo 25mg capsules in their original packaging and store below 25°C. Avoid exposure to moisture or direct sunlight. Handle with care and keep out of reach of children and pets. If a dose is missed, contact a healthcare provider for advice rather than taking extra capsules.

Avoid Interactions

Koselugo may interact with other medications, including strong CYP3A4 inhibitors or inducers. Grapefruit products can affect how selumetinib works, so avoid them during treatment. Always inform your healthcare provider about all medications and supplements you are taking to prevent potential interactions.

References

Frequently Asked Questions

Selumetinib is used to treat certain cancers, such as neurofibromatosis type 1 (NF1) associated plexiform neurofibromas in pediatric patients.

Store Koselugo 25mg capsules below 25°C in their original packaging, away from moisture and direct sunlight.

No, avoid grapefruit or grapefruit products while taking selumetinib, as they may interact with the medication.

Common side effects may include fatigue, nausea, or skin reactions, but these vary by individual.

No, Koselugo 25mg capsules require a prescription and should only be used under medical supervision.

Published by GNH India Pharmaceuticals Limited

Last updated: 18 May 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.